Lead Product(s): VMX-COO1
Therapeutic Area: Hematology Product Name: VMX-COO1
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Ysios Capital
Deal Size: $36.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 08, 2020
Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.